- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05233579
Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS
Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS to Find Biomarkers
FXTAS is a rare genetic progressive neurodegenerative disorder, linked to a trinucleotide repeat expansion in the FMR1 gene. FXTAS is characterized by tremor and ataxia in addition to atrophy and white matter disease in the central nervous system (CNS). In addition to the major clinical observations of intention tremor and gait dysfunction, minor symptoms of parkinsonism, neuropathy, and cognitive decline also significantly impact individuals with FXTAS.
The dietary supplement being tested in this study is called Sulforaphane. It is found in broccoli and similar cruciferous vegetables and may cause some gas and discomfort. This is not a study looking at clinical efficacy but instead a study of molecular outcome measures. Investigators want to get more information about how Sulforaphane affects specific biomolecular markers captured in blood.
In this study, participants will be taking an increasing amount of the Sulphoraphane supplement pills (238mg/tablet), starting at 1 and increasing to 6, every morning at breakfast for 6 months. In addition, there will be a total of 3 visits (Initial, 3-month and 6-month) to the MIND Institute where participants will be evaluated. At each visit (3 total) participants will undergo a battery of medical and neurologic exams which make take 2-3 days to complete each time. Participants and/or their caregivers will also be asked to fill out questionnaires/surveys. At the initial visit and at 6 months, we will collect blood for analysis. Two MRI scans will be done, also at the initial visit and at 6 months.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Randi Hagerman, MD
- Phone Number: 916-703-0247
- Email: rjhagerman@ucdavis.edu
Study Contact Backup
- Name: Ellery Santos
- Phone Number: 916-703-0200
- Email: ersantos@ucdavis.edu
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- UC Davis MIND Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of FXTAS
- Presence of a FMR1 premutation (55 to 200 CGG repeats)
Exclusion Criteria:
- Individuals with severe renal failure (GFR is <60 ml/min/1.73 m^2)
- Significant and current reported substance abuse
- Individuals with substance use disorder (meets 6 or more symptoms of substance use disorder criteria)
- Any subject on hospice or on home oxygen
- Individuals who are pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sulforaphane 1 Tablet
Participants are taking 1 tablet per day.
All participants will start with 1 tablet and continue with 1 tablet for 2 weeks before increasing dose.
|
Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning.
The supplement should be taken around the same time each day.
Other Names:
|
Experimental: Sulforaphane 2 Tablets
Participants will increase dosage to 2 tablets per day after 2 weeks from the start of study participation.
Participants will continue to take 2 tablets for 2 addiitonal weeks before increasing dose.
If participants experience adverse side effects, participants will decrease dosage to 1 tablet.
|
Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning.
The supplement should be taken around the same time each day.
Other Names:
|
Experimental: Sulforaphane 3 Tablets
Participants will increase dosage to 3 tablets per day at 4 weeks from the start of study participation.
Participants will continue to take 3 tablets for 2 addiitonal weeks before increasing dose.
If participants experience adverse side effects, participants will decrease dosage to 2 tablets.
|
Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning.
The supplement should be taken around the same time each day.
Other Names:
|
Experimental: Sulforaphane 4 Tablets
Participants will increase dosage to 4 tablets per day at 6 weeks from the start of study participation.
Participants will continue to take 4 tablets for 2 addiitonal weeks before increasing dose.
If participants experience adverse side effects, participants will decrease dosage to 3 tablets.
|
Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning.
The supplement should be taken around the same time each day.
Other Names:
|
Experimental: Sulforaphane 5 Tablets
Participants will increase dosage to 5 tablets per day at 8 weeks from the start of study participation.
Participants will continue to take 5 tablets for 2 addiitonal weeks before increasing dose.
If participants experience adverse side effects, participants will decrease dosage to 4 tablets.
|
Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning.
The supplement should be taken around the same time each day.
Other Names:
|
Experimental: Sulforaphane
Participants will increase dosage to 6 tablets per day at 10 weeks from the start of study participation.
Participants will continue to take 6 tablets for 2 addiitonal weeks before increasing dose.
If participants experience adverse side effects, participants will decrease dosage to 5 tablets.
|
Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning.
The supplement should be taken around the same time each day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in mitochondrial function via mitochondrial membrane potential and mass.
Time Frame: Baseline, 6 months
|
Primary measures are performed on PBMCs.
Mitochondrial mass and membrane potential will use selected floors and either plate readers or analytical flow cytometry.
|
Baseline, 6 months
|
Changes in mitochondrial function via ATP production
Time Frame: Baseline, 6 months
|
Using PMBCs we will observe in changes in ATP production of various segments of the electron transport chain by utilizing different substrates and coupling between electron transport and ATP production.
|
Baseline, 6 months
|
Observing changes in candidate molecular biomarkers in FXTAS and mitochondrial dysregulation: GRP78
Time Frame: Baseline, 6 months
|
Observing levels in potential molecular biomarkers that affect mitochondrial dysregulation.
GRP78 is a master controller of the mitochondrial ER stress response.
It helps improve Ca2+ transfer and mitochondrial function.
Its level will be measured via ELISA
|
Baseline, 6 months
|
Observing changes in candidate molecular biomarkers in FXTAS and mitochondrial dysregulation: CHOP level
Time Frame: baseline, 6 months
|
Observing levels in potential molecular biomarkers that affect mitochondrial dysregulation.
CHOP is a common downstream indicator of mitochondrial ER stress signals.
It helps improve Ca2+ transfer and mitochondrial function.
Its level will be measured via ELISA
|
baseline, 6 months
|
Observing changes in candidate molecular biomarkers in FXTAS and mitochondrial dysregulation: Bax/Bcl-2 ratio
Time Frame: baseline, 6 months
|
Observing levels in potential molecular biomarkers that affect mitochondrial dysregulation.
Bax/Bcl-2 is a common measure of mitochondrial dysfunction.
It helps improve Ca2+ transfer and mitochondrial function.
It will be measure via Elisa.
|
baseline, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in clinical staging of FXTAS
Time Frame: Baseline, 6 months
|
The standardized neurological examination including frontal release signs, snout, jaw jerk, and palmomental reflex; sensory examination of pinprick and vibration sense; and assessment of alternating movements and cranial nerves.
These measures constitute the FXTAS Rating Scale (FXTAS-RS).
|
Baseline, 6 months
|
Changes in subcortical brain structures damaged in FXTAS through MRI imaging
Time Frame: Baseline, 6 months
|
The measurements will include anatomic volume for quantifying atrophy.
We have developed a robust and efficient method for accurate segmentation of the cerebellum and brainstem and have applied this method to segment the hippocampus, amygdala, basal ganglia, and corpus callosum accurately.
We will continue using this method for quantifying volumes of the white matter in individual lobes and subcortical structures, including the corpus callosum, midbrain, pons, and cerebellar white matter, and calibrating iron depositions in subcortical nuclei (i.e., dentate nucleus, substantia nigra, putamen, and globus pallidus)
|
Baseline, 6 months
|
Changes in FLAIR hypersensitivity volume for subcortical lesions
Time Frame: Baseline, 6 months
|
The measurements will include FLAIR hyperintensity volume for subcortical lesions.
Subcortical hyperintensities will be segmented automatically using Lesion Prediction Algorithm (LPA) from SPM12, which also co-registers FLAIR images to T1 images.
To calculate regional FLAIR hyperintensity volume, we will threshold the generated lesion probability maps at 0.7 and superimpose subcortical and white matter masks to the probability maps using fslmaths from FSL.
|
Baseline, 6 months
|
Changes in Neurological Quality of Life using the Neuro-QoL upper extremity function fine motor scale
Time Frame: Baseline, 6 months
|
The upper extremity function fine motor scale measures the neurological quality of life related to one's ability to carry out various activities involving digital, manual, and reach-related functions ranging from fine motor to self-care.
The assessment is administered as a self-report questionnaire and responses are recorded on a scale of 1 (unable to do) to 5 (without any difficulty).
The assessment will be administered at baseline and at 6 months and any changes in scaled responses will measure changes in neurological quality of life related to the upper extremity functioning.
|
Baseline, 6 months
|
Changes in Neurological Quality of Life using the Neuro-QoL lower extremity functioning mobility scale
Time Frame: Baseline, 6 months
|
The lower extremity function mobility scale measures the neurological quality of life related to one's ability to carry out various activities involving the trunk region and increasing degrees of bodily movement, ambulation, balance, and endurance.
The assessment is administered as a self-report questionnaire and response are recorded on a scale of 1 (unable to do/can't do) to 5 (without any difficulty/no difficulty).
The assessment will be administered at baseline and 6 months and any changes in scaled responses will measure change in neurological quality of life related to the lower extremity functioning.
|
Baseline, 6 months
|
Changes in psychological Issues
Time Frame: Baseline, 6 months
|
The Symptom Checklist-90-Revised (SCL-90-R) is a 90 item self-report psychometric questionnaire created to capture a broad range of psychological problems and has been shown to be sensitive in capturing emotional issues in carriers both with and without FXTAS.
|
Baseline, 6 months
|
Changes in Grip Strength
Time Frame: Baseline, 6 months
|
For the NIH Toolbox Grip Strength Test, participants squeeze the Jamar Plus Digital dynamometer as hard as they can for a count of three.
The dynamometer provides a digital reading of force in pounds.
|
Baseline, 6 months
|
Changes in gait variability
Time Frame: Baseline, 6 months
|
Gait variability will be measured using the GAITRite in which participants will traverse the GAITRite walkway across 6 walking trials for each condition with minimal interruption.
|
Baseline, 6 months
|
Changes in dexterity, tremor, and bradykinesia abnormalities
Time Frame: Baseline, 6 months
|
The Purdue Pegboard test will measure abnormalities in dexterity, tremor, and bradykinesia.
|
Baseline, 6 months
|
Changes in kinetic, postural, and rest tremor upper extremity bradykinesia, hypokinesia, dysrhythmia, and dyskinesias
Time Frame: Baseline, 6 months
|
Participants will perform pre-defined tasks for the Kinesia One test (e.g., finger to nose, finger tapping, wrist rotation, holding arms extended, arms resting on the legs, and hand grasps).
|
Baseline, 6 months
|
Changes in cognitive dysfunction using MoCA
Time Frame: Baseline, 6 months
|
The Montreal Cognitive Assessment (MoCA) will be administered at baseline and 6 months and the MoCA is scored on a scale of 0-30 points.
Changes in the participant's score from the MoCA administered at baseline and the MoCA administered at 6 months will measure whether there are changes in cognitive dysfunction.
|
Baseline, 6 months
|
Changes in cognitive dysfunction using MMSE
Time Frame: Baseline, 6 months
|
The Mini Mental State Exam (MMSE) will be administered at baseline and 6 months.
MMSE is scored on a scale of 0-30 points.
Changes in participant's score from MMSE administered at baseline and MMSE administered at 6 months will measure whether there are changes in mild cognitive dysfunction.
|
Baseline, 6 months
|
Changes in executive function deficits using BDS-2
Time Frame: Baseline, 6 months
|
The Behavioral Dysfunction Scale 2 (BDS-2) is a 9-item assessment of simple motor tasks that scores the participant's completion of each item/task on a scale of 0 (patient demonstrates a complete lack of insight into the accuracy of his or her performance and fails to recognize that errors are being made) to 3 (patient demonstrates good performance with no errors).
The BDS-2 is administered at baseline and 6 months and changes in participant scores will measure changes in executive function deficits.
|
Baseline, 6 months
|
Changes in executive function deficits using COWAT
Time Frame: Baseline, 6 months
|
The Controlled Oral Word Association Test (COWAT) measures executive functioning deficits using verbal fluency and word retrieval tasks.
One's score is calculated by the total number of words listed (1 word = 1 point) Changes in the participant's score from the COWAT administered at baseline and the COWAT administered at 6 months will measure changes in executive function deficits.
|
Baseline, 6 months
|
Changes in frontal executive planning
Time Frame: Baseline, 6 months
|
The Stocking of Cambridge subtest from the CANTAB assessment will be administered to measure deficits in frontal executive planning.
|
Baseline, 6 months
|
Changes in Hippocampus-mediated memory deficits
Time Frame: Baseline, 6 months
|
The Spatial Working Memory and Paired Associates Learning subtest from the CANTAB assessment will be used to measure hippocampus-mediated memory deficits
|
Baseline, 6 months
|
Changes in motor movements
Time Frame: Baseline, 6 months
|
The Choice Reaction Time subtest from the CANTAB assessment will be used to measure motor changes and bradykinesia.
|
Baseline, 6 months
|
Changes in cognitive ability
Time Frame: Baseline
|
Cognitive ability will be measured using the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV).
|
Baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Napoli E, Flores A, Mansuri Y, Hagerman RJ, Giulivi C. Sulforaphane improves mitochondrial metabolism in fibroblasts from patients with fragile X-associated tremor and ataxia syndrome. Neurobiol Dis. 2021 Sep;157:105427. doi: 10.1016/j.nbd.2021.105427. Epub 2021 Jun 19.
- Uddin MS, Mamun AA, Jakaria M, Thangapandiyan S, Ahmad J, Rahman MA, Mathew B, Abdel-Daim MM, Aleya L. Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders. Sci Total Environ. 2020 Mar 10;707:135624. doi: 10.1016/j.scitotenv.2019.135624. Epub 2019 Nov 21.
- Berry-Kravis EM, Harnett MD, Reines SA, Reese MA, Ethridge LE, Outterson AH, Michalak C, Furman J, Gurney ME. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Nat Med. 2021 May;27(5):862-870. doi: 10.1038/s41591-021-01321-w. Epub 2021 Apr 29.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1743661
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fragile X Associated Tremor/Ataxia Syndrome (Fxtas) (Diagnosis)
-
Sheba Medical CenterElMindA LtdRecruitingFragile X Associated Tremor-ataxia Syndrome | FXTASIsrael
-
University of California, DavisNational Institute on Aging (NIA); Forest LaboratoriesCompletedFragile X-Associated Tremor/Ataxia Syndrome | Fragile X Premutation CarriersUnited States
-
Randi J. Hagerman, MDCompletedFragile X-associated Tremor/Ataxia SyndromeUnited States
-
Rush University Medical CenterTerminatedFragile X Associated Tremor-ataxia SyndromeUnited States
-
Rush University Medical CenterCompletedFragile X Tremor/Ataxia SyndromeUnited States
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaboratorsRecruitingMitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditionsUnited States, Australia
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingHemophilia A | Hemophilia B | Cystic Fibrosis | Sickle Cell Disease | Muscular Dystrophy, Duchenne | Fragile X Syndrome | Huntington Disease | Myotonic Dystrophy | Autosomal Recessive Polycystic Kidney Disease | Neurofibromatosis-Noonan Syndrome | Muscular Dystrophy, Becker | Invasive PreNatal Diagnosis in a... and other conditionsFrance
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsEnrolling by invitationPrimary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditionsUnited States
-
UK Kidney AssociationRecruitingVasculitis | AL Amyloidosis | Tuberous Sclerosis | Fabry Disease | Cystinuria | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Bartter Syndrome | Pure Red Cell Aplasia | Membranous Nephropathy | Atypical Hemolytic Uremic Syndrome | Autosomal Dominant Polycystic Kidney Disease | Cystinosis | Nephronophthisis | BK Nephropathy and other conditionsUnited Kingdom
Clinical Trials on Sulforaphane
-
Johns Hopkins UniversityTemple University; State University of New York at BuffaloCompleted
-
University of OxfordQuadram Institute BioscienceRecruitingObesity | Metabolic Syndrome | Non-Alcoholic Fatty Liver DiseaseUnited Kingdom
-
Second Affiliated Hospital, School of Medicine,...UnknownAlzheimer DiseaseChina
-
Andrew ZimmermanJohns Hopkins UniversityCompleted
-
John KirkwoodCompletedMelanoma | Atypical NeviUnited States
-
Central South UniversityStanley Medical Research InstituteCompleted
-
Johns Hopkins UniversityRecruitingSkin AgingUnited States
-
Karolinska InstitutetLantmännenCompletedDiabetes Mellitus, Type 2 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BSweden
-
Xiangya Hospital of Central South UniversityUnknownFrontal Lobe Dysfunction
-
Anders Rosengren, MD PhDCompletedDiabetes Mellitus, Non-Insulin-Dependent